Lonza boosts solid form services for small molecule APIs
![](/46/pdcnewsitem/11/08/55/Lonza-990x525.jpg)
The expanded and refined first-in-human services have been designed to meet the early-stage molecule development of small biopharma players
CDMO Lonza has announced an expansion of its solid form selection services based at its Center of excellence for bioavailability enhancement in Bend, Oregon, US.
The increased service capabilities complement the company's API development and SimpliFiH Solutions first-in-human services consisting of phase-appropriate drug substance and drug product development and manufacture.
The company claims its solid form services offering also enhances its capabilities in meeting accelerated timelines for increasingly complex molecules.
Lonza's Michael Grass, Director of Solid Form Services — Small Molecules, said its methodology is "aimed at thorough solid form selection to ensure that all options for drug substances and drug product are considered early in the development process."
The selection of a lead solid involves the screening and characterization of both chemical forms (salts, cocrystals, solvates) and the associated polymorphs.
Every molecule has a different propensity for polymorphism and to form hydrates and solvates.
The molecule's physicochemical properties and the target product profile dictate the need for screening salts, cocrystals, or bioavailability-enhanced formulations, and the key properties of any solid form: solubility, dissolution rate, manufacturability, stability, and so on.
Effective screening and selection are critical for early-stage and late-stage development to further process risk reduction and/or strengthen intellectual property claims.
Commenting on service expansion, Christian Dowdeswell, VP and Global Head, Commercial Development – Small Molecules, Lonza, said: "Choosing the right solid form and identifying the interplay between solid form and drug product is critical in the rapid advancement of molecules while minimizing risk and cost. Our expanded solid form services offering is designed to meet the early stage molecule development of small biopharma players.”
![Lonza](https://www.cphi-online.com/c248548th_S-comp248548.jpg)
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance